Insmed reported $73.48M in Selling and Administration Expenses for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Acelrx Pharmaceuticals ACRX:US USD 5.26M 1.56M
Alimera Sciences ALIM:US USD 9.86M 46K
Biomarin Pharmaceutical BMRN:US USD 245.74M 28.92M
Cytokinetics CYTK:US USD 53.97M 5.75M
Dynavax Technologies DVAX:US USD 30.38M 1.22M
Gilead Sciences GILD:US USD 2.02B 807M
Heron Therapeutics HRTX:US USD 28.18M 3.94M
Insmed INSM:US USD 73.48M 2.1M
Mirati Therapeutics MRTX:US USD 70.82M 10.02M
Novartis NVS:US USD 3.7B 295M
Regeneron Pharmaceuticals REGN:US USD 660.5M 131.4M
Sarepta Therapeutics SRPT:US USD 120.48M 15.69M
Seattle Genetics SGEN:US USD 216.1M 5.72M
Ultragenyx Pharmaceutical RARE:US USD 72.85M 3.01M
Vertex Pharmaceuticals VRTX:US USD 267.4M 20.6M